Results 181 to 190 of about 48,636 (310)

Bivalent aptamer assemblies: A versatile toolkit for precision targeting of B-cell malignancies. [PDF]

Mol Ther Nucleic Acids
Yin L.
europepmc   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis. [PDF]

Front Immunol
Tariq F, Charavanmuttu Y, Labiba K, Wincup C.   +3 more
europepmc   +1 more source

Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease

The Journal of Pathology, Volume 268, Issue 4, Page 398-412, April 2026.
Abstract Crohn's disease (CD) involves chronic transmural inflammation of the intestines, leading to progressive wall fibrosis with stenosis and luminal obstruction, predominantly in the terminal ileum. Fibrosis is a significant therapeutic challenge, thus improved understanding of localisation, cellular composition, and cell–cell interactions in CD ...
Michael Glinka, Gregory J Wickham, Francesca Nadalin, Kathryn J Kirkwood, Helen Caldwell, Mike Wicks, Bill Hill, Derek Houghton, Mehran Sharghi, Amirhosein Kefayat, Bernard Haggarty, Albert Burger, Richard A Baldock, David J Adams, Irene Papatheodorou, Peter Bankhead, Shahida Din, Mark J Arends   +17 more
wiley   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source

Characterisation of bacteria‐induced colitis and its modulation by probiotics in naked mole rats: a new mammalian model for acute inflammatory disease

The Journal of Pathology, Volume 268, Issue 4, Page 493-511, April 2026.
Abstract Enteropathogenic bacteria are a major cause of morbidity and mortality globally. While mouse models have been indispensable in advancing our understanding of infectious enteric diseases, key differences in intestinal microbiota and immunobiology between mice and humans underscore the need for alternative mammalian models that better ...
Daniel W. Hart, Aik Seng Ng, Patrycja Gazińska, Robert Goldin, Purva Gopal, Nicolize O'Dell, Ahmad Zargar, Lior Pytowski, Shamir Montazid, Chiara Bardella, James E. East, Ian P. Tomlinson, Nadine Koch, Nigel C. Bennett, Shazia Irshad   +14 more
wiley   +1 more source

The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein-Barr Virus-Linked Disease? [PDF]

Open Forum Infect Dis
Onisiforou A.
europepmc   +1 more source

Population‐Based Modeling to Predict Human PK/PD of TAK‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT TAK‐500 is a novel immune cell–directed antibody–drug conjugate (iADC) composed of TAK‐202, an anti‐CCR2 monoclonal antibody, conjugated to the STING agonist dazostinag (TAK‐676), and is designed to stimulate antitumor immunity by reprogramming CCR2‐positive monocytes. To support clinical translation, we developed a population pharmacokinetic (
Anitha Saravanakumar, Rong Deng, Linlin Dong, Satyajeet Haridas, Cindy Q. Xia, Vicky A. Appleman, Adnan O. Abu‐Yousif, Konstantin Piatkov, Haiqing Wang   +8 more
wiley   +1 more source

AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape. [PDF]

Nat Commun
Ansari MS, Chauhan V, Singh A, Akhtar A, Chaudhary N, Tyagi R, Divya, Husain K, Sharma S, Alam R, Shakir M, Pracha M, Anjum S, Nadeem M, Taneja P, Faizan MI, Azmi I, Iyer AR, Gupta P, Nafiz M, Ali S, Uddin IM, Javid M, Bhat ZA, Palani HK, Srivastava AK, Mabalirajan U, Mathews V, Husain M, Ramalingam S, Kharya G, Ahmad T.   +31 more
europepmc   +1 more source

Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches

European Journal of Haematology, Volume 116, Issue 4, Page 368-379, April 2026.
ABSTRACT Follicular lymphoma (FL), traditionally considered an indolent yet incurable malignancy, is experiencing a substantial evolution in its therapeutic landscape with the emergence of chemo‐free treatment strategies. These novel approaches challenge conventional chemotherapy‐based paradigms and offer promising alternatives for both newly diagnosed
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source